Angiodynamics Stock Price, News & Analysis

AngioDynamics, Inc. (NASDAQ: ANGO) announced it will report its second quarter financial results for fiscal year 2022 on January 6, 2022, prior to market open. The management will conduct a conference call at 8:00 a.m. ET on the same day to discuss these results. Interested participants can join by calling 1-877-407-0784 domestically or +1-201-689-8560 internationally, using passcode 13725681. The call will also be accessible via webcast on AngioDynamics' website, with a replay available later that day.

AngioDynamics reported fiscal 2022 Q1 results with net sales of $77.0 million, a 9.6% increase year-over-year. Gross margin rose to 52.1%, up 120 basis points. The company reported a GAAP loss per share of $0.18 and an adjusted loss of $0.02. Notably, Med Tech sales surged 68.0% to $17.6 million, driven by the Auryon platform. U.S. sales increased 19.1%, but international sales fell 22.4%. The company raised its FY2022 sales guidance to $310-$315 million.

AngioDynamics, Inc. (NASDAQ: ANGO) will announce its first-quarter fiscal year 2022 financial results on September 30, 2021, before market opening. A conference call is scheduled for 8:00 a.m. ET on the same day to discuss these results. Investors can participate by dialing 1-877-407-0784 for domestic calls or +1-201-689-8560 for international calls, using passcode 13723182. The call will also be available via webcast on AngioDynamics' website.

AngioDynamics (NASDAQ: ANGO) announced that CEO Jim Clemmer and CFO Stephen Trowbridge will present at the 41st Annual Canaccord Genuity Virtual Growth Conference on August 11, 2021, at 9:00 a.m. ET. A live webcast of the presentation will be available on the company’s website and can be replayed afterward. AngioDynamics specializes in minimally invasive medical devices for vascular access and oncology, offering a range of products including ablation systems and vascular access solutions.

AngioDynamics (ANGO) reported Q4 fiscal 2021 net sales of $76.8 million, up 31.7% year-over-year. Endovascular Therapies saw a 72.3% increase, driven by Auryon and AngioVac sales, while oncology sales rose 14.2%. Despite these gains, the company incurred a net loss of $19.5 million, including a $14.0 million write-off. For FY 2021, net sales reached $291.0 million, a 10.2% increase, but net loss was $31.5 million. Looking ahead, FY 2022 guidance estimates net sales of $305 to $310 million and adjusted EPS of $0.00 to $0.05, reflecting ongoing investment in product launches.

AngioDynamics (NASDAQ: ANGO) announced its upcoming virtual Investor & Technology Day on July 13, from 9:30 to 11:30 a.m. ET. The event will feature presentations from the executive leadership team, discussing the company’s growth strategy, key technology platforms, and financial goals. Interested parties can register via the company’s website. A live webcast and archive of the presentation will also be available on the Investors section of the AngioDynamics website.

AngioDynamics, Inc. (NASDAQ: ANGO) will report its financial results for Q4 and fiscal year 2021 on July 13, 2021, before market open. A conference call is scheduled for 8:00 a.m. ET for management to discuss these results. Investors can dial in using a specified number or access through a webcast on the company's website. Additionally, AngioDynamics will host a virtual Investor & Technology Day on the same day at 9:30 a.m. ET. Details and registration information will be provided on their website.

AngioDynamics, Inc. (NASDAQ: ANGO) announced that it received 510(k) clearance from the FDA for the AlphaVac Mechanical Thrombectomy System, designed for non-surgical removal of thrombi or emboli. The commercial release is anticipated in the second half of 2021. Additionally, the Company will report its fourth quarter and fiscal year 2021 financial results on July 13, 2021, with a conference call scheduled at 8:00 a.m. ET, followed by a virtual Investor and Technology Day at 9:30 a.m. ET.

AngioDynamics, Inc. (NASDAQ: ANGO), a top provider of minimally invasive medical devices, announced Jim Clemmer, President and CEO, will present at the UBS Virtual Global Healthcare Conference on May 25, 2021, at 12:00 p.m. ET. The live webcast can be accessed through the company’s website and will be available for replay afterward.

The company specializes in devices for vascular access, peripheral vascular disease, and oncology, with a product range that includes ablation systems and drainage products. For further details, visit www.angiodynamics.com.